Our findings that patients with NSCLC that expressed high PDL1 and low p53 levels had lower survival rates than did patients with low PDL1/high p53 tumors and those with high miR-34a/high p53 had better survival rates than those with low miR-34a/low p53 or simply low p53 expression have potential clinical applications because the concomitant status of p53 and PDL1 expression could be useful biomarkers of response to therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.